Literature DB >> 24980773

Iatrogenic comorbidity in childhood and adolescence: new insights from the use of antidepressant drugs.

Emanuela Offidani1, Giovanni A Fava, Nicoletta Sonino.   

Abstract

The term "iatrogenic comorbidity" refers to unfavorable modifications in the course of an illness, with regard to its characteristics and responsiveness, which may be related to previous treatments. Some iatrogenic adverse events arising from either pharmacotherapy or psychotherapy cannot be subsumed under the traditional rubric of adverse effects and require careful evaluation. Children and adolescents are generally more likely to experience adverse health consequences after drug treatment. The use of antidepressant drugs in this age group may cause potential long-term detrimental effects, such as mood elevation that does not subside when drugs are discontinued and may predispose to the development of a bipolar disorder. The concept of iatrogenic comorbidity in children and adolescents has heuristic value in weighing potential benefits and risks associated particularly with psychotropic treatments.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24980773     DOI: 10.1007/s40263-014-0184-0

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  27 in total

1.  A pediatric perspective on the unique vulnerability and resilience of the embryo and the child to environmental toxicants: the importance of rigorous research concerning age and agent.

Authors:  Robert L Brent; Susanne Tanski; Michael Weitzman
Journal:  Pediatrics       Date:  2004-04       Impact factor: 7.124

2.  Emerging clinical trends and perspectives on comorbid patterns of mental disorders in research.

Authors:  Giovanni A Fava; Eliana Tossani; Per Bech; Carmen Berrocal; Guy Chouinard; Claudio Csillag; Hans-Ulrich Wittchen; Winfried Rief
Journal:  Int J Methods Psychiatr Res       Date:  2014-01       Impact factor: 4.035

Review 3.  Negative effects from psychological treatments: a perspective.

Authors:  David H Barlow
Journal:  Am Psychol       Date:  2010-01

Review 4.  Developments in pediatric psychopharmacology: focus on stimulants, antidepressants, and antipsychotics.

Authors:  Christoph U Correll; Christopher J Kratochvil; John S March
Journal:  J Clin Psychiatry       Date:  2011-05       Impact factor: 4.384

5.  The risks and benefits of antidepressants to treat pediatric-onset depression and anxiety disorders: a developmental perspective.

Authors:  James F Leckman
Journal:  Psychother Psychosom       Date:  2013-03-21       Impact factor: 17.659

6.  Comorbidity and multimorbidity need to be placed in the context of a framework of risk, responsiveness, and vulnerability.

Authors:  W Scott Richardson; Lynn M Doster
Journal:  J Clin Epidemiol       Date:  2014-03       Impact factor: 6.437

Review 7.  Excessive mood elevation and behavioral activation with antidepressant treatment of juvenile depressive and anxiety disorders: a systematic review.

Authors:  Emanuela Offidani; Giovanni A Fava; Elena Tomba; Ross J Baldessarini
Journal:  Psychother Psychosom       Date:  2013-03-21       Impact factor: 17.659

Review 8.  Behavioral toxicity of antipsychotic drugs.

Authors:  T Van Putten; S R Marder
Journal:  J Clin Psychiatry       Date:  1987-09       Impact factor: 4.384

9.  THE PRE-THERAPEUTIC CLASSIFICATION OF CO-MORBIDITY IN CHRONIC DISEASE.

Authors:  A R Feinstein
Journal:  J Chronic Dis       Date:  1970-12

Review 10.  Innovative trends in the design of therapeutic trials in psychopharmacology and psychotherapy.

Authors:  Giovanni A Fava; Elena Tomba; Eliana Tossani
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-10-31       Impact factor: 5.067

View more
  1 in total

1.  Evaluation of Potentially Prolactin-Related Adverse Events and Sexual Maturation in Adolescents with Schizophrenia Treated with Paliperidone Extended-Release (ER) for 2 Years: A Post Hoc Analysis of an Open-Label Multicenter Study.

Authors:  Srihari Gopal; Rosanne Lane; Isaac Nuamah; Margaret Copenhaver; Jaskaran Singh; David Hough; Mark Bach; Adam Savitz
Journal:  CNS Drugs       Date:  2017-09       Impact factor: 5.749

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.